4D-150 Delivers Durable Two-Year Wet AMD Efficacy, Driving 87% Treatment Burden Reduction in Key Subgroup
FDMT has more than doubled off its 52-week low of $4.145.
Summary
4D Molecular Therapeutics reported positive two-year data for its lead gene therapy 4D-150 in wet AMD, showing an 87% reduction in treatment burden in the recently diagnosed subgroup and a durable safety profile, supporting ongoing Phase 3 trials.
Key Events · Product Development and Regulatory · FDMT
-
Two-Year Efficacy Data
In the PRISM Phase 2b trial, 4D-150 demonstrated an 87% reduction in treatment burden in the recently diagnosed subgroup (1.6 mean supplemental injections vs. 12.0 projected with aflibercept) and 78% in the overall cohort, with maintained visual acuity and retinal anatomy.
-
Durable Safety Profile
Across 71 patients followed for 2 to over 4 years, no new cases of 4D-150-related intraocular inflammation appeared after 28 weeks post-dosing, and there were no instances of hypotony, endophthalmitis, vasculitis, or choroidal effusions.
-
Phase 3 De-Risking
The recently diagnosed subgroup results closely mirror the population enrolled in the ongoing 4FRONT Phase 3 trials, supporting the potential for a best-in-class profile and reducing regulatory risk.
-
Market Opportunity
Wet AMD affects millions globally, and a single-dose gene therapy that dramatically reduces injection burden could capture significant share in a multi-billion-dollar market.
Analysis · FDMT · Life Sciences
Two-year data from the PRISM Phase 2b trial of 4D-150 in wet AMD underscore durable efficacy and a meaningful drop in treatment burden. In the recently diagnosed subgroup—which most closely mirrors the ongoing Phase 3 population—patients needed a mean of only 1.6 supplemental injections over two years, compared with 12.0 projected for standard aflibercept, an 87% reduction. The safety profile remains clean, with no new inflammation cases emerging after 28 weeks. These results de-risk the Phase 3 program and bolster the case for a transformative gene therapy in a large market.
At the time of this filing, FDMT was trading at $11.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $574.5M. The 52-week trading range was $4.15 to $14.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.